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Maternal immune activation (MIA) during fetal development leads to behavioral
and psychological disorders in the offspring. Concomitantly, insufficient supply of
polyunsaturated fatty acids (PUFAs) is suspected to contribute to early neuronal
maldevelopment due to the immune modulatory capabilities of PUFAs. However, human
data are missing considering both of these aspects and their impact on children’s
behavioral outcomes. In line, this study aimed to elucidate the influence of gestational
cytokines and PUFA-containing lipids during late pregnancy on behavioral sequelae
in childhood, particularly focusing on an immune activation shaped by a history of
maternal atopic diseases instead of a pathogen-mediated immune response. Based on
the prospective mother-child cohort LINA we assessed the unstimulated blood cytokine
profiles and concentrations of PUFA-containing lipids of 293 mothers at the 34th week
of pregnancy. Maternal history of atopic diseases was obtained from questionnaires
and behavior in eight-year-old children was assessed by the standardized Strength
and Difficulties Questionnaires (SDQ) generating scores for hyperactivity/inattention,
emotional symptoms, conduct problems, and peer relationship problems. Elevated
IL-13 increased the risk for the child to show behavioral difficulties, in particular,
hyperactive/inattentive behavior [adj. OR (95% CI): 2.47 (1.51–4.02), n = 255 vs. 38]
at the age of eight years. Although the presence of maternal atopic dermatitis (AD)
was associated with increased gestational IL-13 concentrations [adj. MR (95% CI): 1.17
(1.04–1.32)], no effect on children’s behavioral difficulties was observed. However, a
decrease in the PUFA containing lipid species PC aa C38:6 was not only associated with
an increased gestational IL-13 concentration but also mediated the indirect effect of low
PC aa C38:6 concentrations on children’s abnormal behavior independent of maternal
AD. We additionally assessed whether maternal IL-13 and PC aa C38:6 concentrations
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translate their effect by altering children’s cord blood PC aa C38:6 and IL-13. While also
the children’s cord blood IL-13 was related to children’s behavior, no effect of children’s
PC aa C38:6 was observed. This is the first study demonstrating that elevated gestational
IL-13 increases the risk for children to develop behavioral difficulties. Analyses suggest
that a reduced supply of gestational PC aa C38:6 contributes to elevated gestational
IL-13 leading to behavioral sequelae in the offspring.
Keywords: hyperactivity, inattention, SDQ, maternal, atopic dermatitis, inflammation, prenatal, PUFA
INTRODUCTION
Fetal brain development is highly sensitive to maternal immune
activation (MIA). As maternal cytokines, hormones, as well
as immune cells can cross the placenta—commonly referred
to as “vertical transfer”—changes in the maternal immune
status can significantly affect fetal development (1). MIA
by infections during pregnancy has been shown to have a
profound impact on developing neural circuits and has been
linked to the pathogenesis of behavioral and psychological
disorders in the offspring (1, 2) like schizophrenia, autism
spectrum disorder (ASD), or attention-deficit/hyperactivity
disorder (ADHD) (3–5). These associations have been
demonstrated in epidemiological studies and were further
characterized in rodent models (5–7). Thereby, several
lines of evidence suggest that in particular gestational
cytokines act as mediators in altered fetal neuroimmune
interactions leading to neurobehavioral sequelae in the
offspring (8).
Although various insults can trigger changes in the maternal
immune homeostasis, best studied are changes in the profile of
classical pro-inflammatory cytokines like IL-6, IL-8, or TNFα
as a consequence of bacterial or viral infections and their
impact on fetal brain development (9–12). Complementary
studies in mice support the notion that offspring behavioral
abnormalities are attributable to a maternal inflammatory
immune response mediated by maternal-fetal cytokine signaling
(13). For instance, it has been demonstrated that maternal IL-
6 acting via placental IL-6 receptor signaling (14) is responsible
for the offspring’s development of social and behavioral deficits
induced by injection of the viral mimic poly(I:C) into pregnant
mice (15).
However, growing evidence suggests that immune activation
in the mother also in the absence of pathogens, for instance, due
to maternal autoimmune diseases, or an atopic phenotype, may
have neuropathological consequences for the child. Recently,
Nielsen et al. demonstrated in a Danish nationwide explorative
study including 983,680 children that a history of maternal
autoimmune diseases such as type 1 diabetes and psoriasis was
associated with an increased risk for the offspring to develop
ADHD (16). Maternal psoriasis has also been related to an
increased risk for ASD in the child (17). In their epidemiological
study, Croen et al. could also show that maternal asthma and
allergy can contribute to an increased risk for the child to develop
ASD (17).
Although adverse effects of MIA during pregnancy have
been well described as risk factors for the development of
schizophrenia, ASD, or epilepsy in the offspring, there is little
information on the contribution of maternal atopic diseases in
particular to the highly prevalent neurodevelopmental disorder
ADHD characterized by hyperactivity and inattention. In
particular, human data investigating the association between
gestational cytokine levels and ADHD development are missing.
Further important mediators affecting both the maternal
immune status as well as the fetal brain development are
poly-unsaturated fatty acids (PUFAs). During pregnancy, high
amounts of PUFAs are transported across the placenta to
ensure proper brain development, particularly during the
last trimester of pregnancy, which is characterized by rapid
neuron development and wiring (18, 19). Already Lamptey
and Walker could show in a rodent model that a deficiency
of PUFAs in the maternal diet led to impaired learning
and memory functions in the offspring (20). Moreover,
animal studies showed that deficiency of omega-3 fatty acids
during gestation and lactation induce a prodromal state
of schizophrenia (21), impaired spatial memory (6), and
prolonged escape latency in the Morris water maze test
(22), while omega-3 fatty acid supplementation improved
the performance of the animals (23). On the other hand,
due to their immunomodulatory activity gestational PUFA
supplementation has beneficial effects in animal models of MIA-
induced ASD and schizophrenia. Although in humans benefits
of PUFA supplementation during pregnancy are ambiguous
(24), in ADHD patients PUFA supplementation might improve
symptoms (25).
In the present study, we investigated the potential
contribution of maternal atopy-related immune inflammation
on behavioral outcomes including hyperactivity/inattention
in eight-year-old children of the German population-based
prospective mother-child cohort LINA using the standardized
Strength and Difficulties Questionnaire (SDQ). The SDQ is an
internationally accepted instrument assessing child behavior
and has been proven as a valid screening tool for ADHD and
hyperactivity/inattention in children (26–30). We investigated
the history of maternal allergic diseases such as atopic dermatitis
and asthma as potential contributing factors to maternal immune
response and the different behavioral difficulty scales of the SDQ.
As we not only have information on the maternal cytokine profile
during pregnancy but also on the gestational concentrations
of different lipid species, we were able to study the interplay
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between these two immune modulators and their potential
impact on the development of behavioral difficulties in children.
METHODS
Study Cohort
This study is based on the prospective mother-child cohort
LINA (Lifestyle and Environmental Factors and their Influence
on Newborn’s Allergy Risk), for which 629 mother-child pairs
were recruited from March 2006 until December 2008 in
Leipzig, Germany. Mothers suffering from severe immune or
infectious diseases during pregnancy were excluded from the
study. Standardized questionnaires (self-administered by the
parents) on lifestyle/environmental exposures, living conditions,
parental, and children’s atopic diseases were recorded during
pregnancy and annually after birth. Maternal atopic diseases were
defined according to the questions “Did you ever suffer from
asthma?,” “Did you ever suffer from atopic dermatitis?” included
in the pregnancy questionnaire. Accordingly, the maternal
control group for asthma did not report asthma and the control
group for AD did not report AD. Information on potential
confounding variables was also obtained from this questionnaire.
Blood samples were obtained during a clinical investigation of the
mother in the 34th week of gestation and for the children at the
time of birth (cord blood) and annually after birth at scheduled
clinical visits. This study was carried out in accordance with the
declaration of Helsinki and was approved by the Institutional
Review Board of the University of Leipzig (046-2006, 150/14-ff).
Participation in the study was voluntary and informed written
consent was given by the parents.
This study is based on a LINA subcohort considering all
children, for whom maternal blood samples obtained at the 34th
week of gestation and SDQ information at children’s age of eight
were available (n= 293).
Behavioral Evaluation (SDQ)
Behavioral evaluation of eight-year-old children was based on
the standardized Strength and Difficulties Questionnaire (SDQ)
assessing emotional, mental, and behavioral problems.
Parents completed the 25-item SDQ questionnaire. Each
question could be answered on a three-point scale (0, 1, or 2;
“not true,” “somewhat,” or “certainly true”). Five subscores were
defined based on five out of the 25 items and corresponded to
the following behavioral categories; “hyperactivity/inattention,”
“emotional symptoms,” “conduct problems,” “peer relationship
problems,” and “prosocial behavior” as developed by Goodman
et al. (31). The hyperactivity/inattention subscale is a valid
predictor of clinically diagnosed ADHD (32) and is composed of
five items (“Restless, overactive, cannot stay still for long”;
“Constantly fidgeting or squirming”; “Easily distracted,
concentration wanders”; “Thinks things out before acting”; and
“Sees tasks through to the end, good attention span”) addressing
the three core symptoms of ADHD diagnosis criteria according
to the Diagnostic and Statistical Manual of Mental Disorders—
Fourth Edition (DSM-IV—American Psychiatric Association,
1994), namely inattention and hyperactivity/impulsiveness
behavior (26).
A score for each of these subscales was calculated by summing
the scored answers of each of the five items (range 0–10).
A total difficulties score (TDS) was obtained by summing up
the four subscores “emotional symptoms,” “conduct problems,”
“hyperactivity/inattention,” and “peer relationship problems” for
each child ranging from 0 to 40. Subsequently, based on the
normalization of parent-reported SDQ of the German-wide
national study, the children were classified as showing “normal,”
“borderline,” or “abnormal” behavior based on Woerner et al.
(33). Since the prosocial behavior score is not included in the TDS
calculation, we omitted the prosocial subscale in all subsequent
analyses (31). For statistical analyses, children with borderline
and abnormal behavior were combined.
Cytokine Measurement
Cord blood and maternal heparinized blood obtained at
the 34th week of gestation by venous puncture was used
for cytokine measurements. Aliquots of these samples
were diluted with RPMI medium and incubated for 4 h
at 37◦C. After centrifugation, resulting supernatants were
used to determine unstimulated cytokine concentrations
in [pg/ml] (maternal: IL-4, IL-5, IL-6, IL-8, IL-10, IL-12,
IL-13, TNFα, IFNγ, MCP-1; cord blood: IL-13) using the
BD CBA Human Soluble Flex Set system (BD Bioscience,
Heidelberg, Germany) as previously described (34, 35).
Cytokine concentrations below the detection limit were
assigned a value that was half of the detection limit prior
to ln-transformation.
Measurement of Blood Lipids
Metabolomic analysis was performed with 10 µl of blood
serum (maternal: 34th week of gestation; infantile: cord blood)
by using the AbsoluteIDQ p180 Kit (Biocrates Life Science
AG, Innsbruck, Austria) as described elsewhere (36). Briefly,
in total 180 compounds were measured including sugars,
amino acids, acylcarnitines, biogenic amines, and lipids. For
lipid analysis, the AbsoluteIDQ p180 Kit employs a flow
injection analysis tandem mass spectrometry (FIA-MS/MS) and
generates lipid class-specific fragment ions. As such, each of
the detected signals is a sum of different isobaric/isomeric
lipids. Measured lipid species include phosphatidylcholines
(PC), lysophosphatidylcholines (LysoPC), and sphingomyelins
(SM). In the current study, we focused on lipids containing
polyunsaturated fatty acids (PUFAs). Therefore, only PC
lipid species with at least three double bonds, and LysoPC,
or SM lipids containing at least two double bonds, were
considered to ensure inclusion of lipids containing at least
one PUFA. To this end, subsequent analyses were restricted
to n = 43 PUFA containing lipids. The list of maternal
lipid species, which were included in the analyses is provided
in Table 4.
Statistical Analysis
Chi-square was used to test for equal parameter distribution in
the analyzed subcohort and the entire LINA cohort.
Children’s behavioral scores were considered either as
continuous variables in multiple regression analyses or as
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TABLE 1 | Characteristics of the entire LINA cohort and the investigated
subcohort.
Entire cohort
n = 629 (%)a
Subcohort
n = 293 (%)a
p-
value#
Gender of the child
Male 330 (52.5) 151 (51.5) 0.848
Female 299 (47.5) 142 (48.5)
Household income*
Low 139 (22.1) 58 (19.8) 0.230
Intermediate 326 (51.8) 160 (54.6)
High 125 (19.9) 75 (25.6)
Tobacco smoke exposure during pregnancy**
(Almost) daily 48 (7.6) 13 (4.4) 0.191
Occasionally 47 (7.5) 22 (7.5)
Never 534 (84.9) 258 (88.1)
Parental education level***
Low 16 (2.5) 3 (1.0) 0.066
Intermediate 144 (22.9) 53 (18.1)
High 469 (74.6) 237 (80.9)
Alcohol consumption during pregnancy
Never 353 (56.1) 166 (56.7) 0.935
Ever 276 (43.9) 127 (43.3)
Maternal history of atopic
diseases
n/N (%) n/N (%)
Asthma 71/627 (11.3) 30/293 (10.2) 0.706
Atopic dermatitis 112/623 (18.0) 50/292 (17.1) 0.824
aNumbers may be different from the total sum due to missing data.
#p-value from chi-squared test for cross relationship.
*Low income: <1,500e per month, intermediate income: 1,500–3,000e per month, high
income: >3,000e per month.
**Answers based on the question “Did you or anybody else smoke inside your home during
the last 12 months?”
***Low: nine years of schooling or less “Hauptschulabschluss”, intermediate: 10 years of
schooling “Mittlere Reife”, high: 12 years of schooling or more “(Fach-)hochschulreife.”
categorical variables in logistic regression analyses. Logistic
regression models adjusted for potential confounding variables
were applied to study the association of gestational cytokines,
cord blood IL-13, maternal atopic diseases, or PC aa C38:6
lipid (gestational and cord blood) on children’s behavioral
abnormalities. Adjusted multiple regression models were applied
for the association analyses of continuous variables such
as cytokine concentrations, TDS or hyperactivity/inattentive
scores. To evaluate the relationship between PUFA containing
lipid species and IL-13 concentrations during pregnancy,
Spearman correlations were applied. To study whether maternal
IL-13 or cord blood IL-13 mediates the indirect effect
of the PUFA containing lipid species “PC aa C38:6” on
children’s TDS or hyperactivity/inattention, mediation analyses
were conducted (PROCESS macro v2.16.3 for SPSS, www.
processmacro.org) using a bootstrap approach with 5,000
samples to estimate the statistical significance of the indirect
effect as percentile-corrected 95% CIs (37). For multiple
regression and mediation analyses, all continuous variables
were ln-transformed.
TABLE 2 | Prevalence of children with abnormal/borderline behavior at the age
of eight.
SDQ categorya n/N (%)
Hyperactivity/inattention 38/293 (13.0)
Emotional symptoms 50/293 (17.1)
Conduct problems 30/293 (10.2)
Peer relationship problems 19/293 (6.5)
TDSb 37/293 (12.6)
aCategorization in “normal” and “borderline/abnormal” based on (33).
bThe score of “total difficulties” is the sum of the categories “hyperactivity/inattention,”
“emotional symptoms,” “conduct problems,” and “peer relationship problems.”
In all models, except those investigating the association
between maternal atopic diseases and IL-13 concentration,
we considered the potential confounding factors known
to influence children’s behavior (38–42): gender, parental
educational level, household income, tobacco smoke exposure
during pregnancy, and alcohol consumption during pregnancy.
For multiple regression analyses assessing the influence of
maternal atopic diseases on IL-13, the maternal age, the
maternal education level, the tobacco smoke exposure during
pregnancy, the household income, and cat keeping were
included in the models as confounding factors (all derived
from questionnaires).
For the comparison of groups, either the Kruskal-Wallis test
or Mann-Whitney U-test were applied. Whenever applicable
we performed multiple test correction by Bonferroni. P ≤
0.05 was considered significant. Analyses were performed
in either STATISTICA 13.3 for Windows (Dell Inc., USA),
GraphPad Prism version 7.00 for Windows (GraphPad
Software, USA), SigmaPlot version 14.0 (Systat Software
GmbH, Germany), or IBM SPSS Statistics version 25 (IBM
Corps., USA).
RESULTS
General Study Characteristics and
Prevalence of Abnormal Behavior
In total, 334 children participated in the LINA eight-year follow-
up investigation. For 293 of these children SDQ information,
as well as maternal blood samples collected during the 34th
week of pregnancy, were available. General characteristics of
the analyzed subcohort (n = 293) and the entire LINA cohort
(n = 629) are given in Table 1. There was no selection
bias in the subcohort compared to the total cohort. Overall,
12.6% (n = 37) of the children were classified as showing
abnormal or borderline behavior based on the German cut-
off for the total difficulties score (TDS) (33), which is in
line with previous observations reporting that 13.8% of 10
year-old and 13.0% of 6–11-year-old children showed either
abnormal, or borderline behavior based on TDS classification
(43, 44). According to the standardized classification provided by
Woerner et al. (33) for the different SDQ subscores, 13% (n =
38) of the children were hyperactive/inattentive, 17.1% (n = 50)
showed emotional symptoms, 10.2% (n = 30) showed conduct
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FIGURE 1 | Risk increase for the development of abnormal behavior at the age of eight in relation to gestational cytokine profile. Classification of the children in normal
and abnormal behavior is based on (A) TDS (256 controls vs. 37 children with abnormal behavior) or (B) the hyperactivity/inattention subscore (255 controls vs. 38
children with hyperactive/inattentive behavior). Box plots show gestational IL-13 concentrations of children with normal, borderline, or abnormal behavior (median with
25/75% quartile; whiskers represent the non-outlier range). Differences in numbers are due to the different cut-offs determining normal and abnormal behavior applied
for the subscales. Cut-offs were obtained from Woerner et al. (33). Logistic regression models comparing normal vs. abnormal/borderline behavior were adjusted for
gender, parental educational level, household income, prenatal tobacco smoke exposure, and alcohol consumption during pregnancy. For analyses, cytokine data
were ln-transformed (#p-values adjusted for Bonferroni correction, n(tests) = 10).
problems, and 6.5% (n= 19) had difficulties in peer relationships
(Table 2).
Gestational Cytokine Pattern and
Children’s Development of Abnormal
Behavior
We first applied an adjusted logistic regression model to
determine whether maternal cytokines (IL-4, IL-5, IL-
6, IL-8, IL-10, IL-12, IL-13, MCP-1, TNFα, and IFNγ)
measured at the 34th week of pregnancy are linked to the
development of abnormal children’s behavior in later life.
Among the ten cytokines investigated, an increased IL-13
protein concentration was associated with an increased
risk for the child to show abnormal behavior at the age
of eight based on the TDS [OR (95% CI): 1.90 (1.21–
2.97); adj. OR (95% CI): 1.98 (1.24–3.14), n = 256 vs. 37,
Figure 1A].
Categorizing the children in those showing
abnormal/borderline behavior based on the different
subscales of the SDQ, it became apparent that increased
prenatal-maternal IL-13 exposure is in particular associated
with hyperactivity/inattention of children [OR (95%
CI): 2.18 (1.38–3.45); adj. OR (95% CI): 2.47 (1.51–
4.02), n = 255 vs. 38, Figure 1B]. No association of
maternal IL-13 to the other subscales of the SDQ was
observed (Supplementary Table 1).
We furthermore saw an increased risk for the children to
show hyperactive/inattentive behavior at the age of eight in
association to elevated gestational IFNγ [OR (95% CI): 1.91
(1.18–3.07); adj. OR (95% CI): 1.90 (1.17–3.09)] and IL-4
concentrations [OR (95% CI): 1.68 (1.04–2.72); adj. OR (95%
CI): 1.63 (0.99–2.67)]. However, the association between IL-
4/IFNγ/IL-13 and children’s hyperactivity/inattention remained
statistically significant only for IL-13 following multiple test
correction (Figure 1B).
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FIGURE 2 | Association between maternal atopic diseases and gestational IL-13. (A) Box plots show gestational IL-13 concentrations of mothers suffering from
asthma or AD in comparison to their respective controls (median with 25/75% quartile; whiskers represent the non-outlier range, *p < 0.05 from Mann-Whitney U
test). (B) Multiple regression models adjusted for maternal age, maternal educational level, tobacco smoke exposure during pregnancy, household income, and cat
keeping. For analyses, IL-13 concentrations (dependent variable) were ln-transformed.
TABLE 3 | Risk increase for children to develop behavioral abnormalities at the age of eight in relation to maternal atopic dermatitis diagnosis.





Hyperactivity/inattention 254/38 1.91 (0.86–4.25) 0.111 1.61 (0.70–3.74) 0.262
Emotional symptoms 242/50 1.08 (0.48–2.39) 0.857 1.05 (0.47–2.37) 0.905
Conduct problems 262/30 0.72 (0.24–2.18) 0.562 0.57 (0.18–1.81) 0.340
Peer relationship problems 273/19 1.81 (0.62–5.30) 0.277 2.01 (0.66–6.12) 0.219
TDS 255/37 2.34 (1.07–5.14) 0.033 2.13 (0.94–4.82) 0.069
*Logistic regression models were adjusted for gender, parental educational level, household income, prenatal tobacco smoke exposure, and alcohol consumption during pregnancy.
The difference in case and control numbers are due to the different cut-offs determining normal and abnormal behavior applied for the subscales. Cut-offs were obtained
from Woerner et al. (33).
Association of Maternal Atopic Diseases
With Gestational IL-13 and Children’s
Behavior
We went on to investigate the influence of maternal atopic
diseases, such as asthma, and AD on gestational IL-13
concentrations and the development of behavioral abnormalities
in their offspring. The median concentration (and IQR) of
gestational IL-13 was 3.85 pg/ml (1.50–6.02 pg/ml) in asthmatic
mothers (n = 30) and 5.43 pg/ml (1.50–8.09 pg/ml) in mothers
suffering of AD (n = 50). For asthma controls (n = 263)
the median concentration was 4.10 pg/ml (1.5–6.80 pg/ml)
and 3.88 pg/ml (1.50–6.30 pg/ml) for AD controls, respectively
(Figure 2A). Adjusted multiple regression analysis revealed no
association of maternal asthma with gestational IL-13. However,
a significant influence of maternal AD on increased IL-13
concentration [MR (95% CI): 1.13 (1.01–1.27); adj.MR (95% CI):
1.17 (1.04–1.32), Figure 2B] was observed, which was sustained
even after additionally adjusting for asthma [adj.MR (95% CI)
=1.18 (1.04–1.33), n= 292, p= 0.007].
Children of mothers suffering from AD showed an increased
risk for the development of abnormal or borderline behavioral
problems at the age of eight only in trend [TDS: adj. OR (95%CI):
2.13 (0.94–4.82), n = 255 vs. 37, Table 3], while no association
of maternal AD with the development of hyperactive/inattentive
behavior was observed. In line, maternal asthma had no impact
on children’s behavior (Supplementary Table 2).
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FIGURE 3 | Association between gestational IL-13 and children’s TDS or hyperactivity/inattention score in children born to mothers with or without a history of atopic
dermatitis (AD). (A) Forest plots consider either children of mothers with a history of AD (left panel) or children of mothers without a history of maternal AD (right panel).
*MRs from multiple regressions adjusted for gender, parental educational level, household income, tobacco smoke exposure during pregnancy, and alcohol
consumption during pregnancy. IL-13 data were ln-transformed. (B) Box plots show gestational IL-13 concentrations of children with normal, borderline, or abnormal
behavior (median with 25/75% quartile; whiskers represent non-outlier range), for TDS (upper panel), and hyperactivity/inattention subscores (lower panel). Differences
in numbers are due to the different cut-offs determining normal and abnormal behavior applied for the subscales. Cut-offs were obtained
from Woerner et al. (33).
In addition, the significant association between gestational IL-
13 and the hyperactivity/inattention score was still observed in
children from mothers with a positive history of AD [adj. MR
(95% CI): 1.32 (1.01–1.72), n = 50], as well as in children of
mothers without AD [hyperactivity/inattention: adj. MR (95%
CI): 1.25 (1.10–1.42), n = 242]. In the latter, elevated IL-13
concentrations were related to an increase in the TDS as well
[TDS: adj. MR (95% CI): 1.23 (1.09–1.40), n= 242; Figure 3].
PUFA Species/Gestational IL-13 and
Offspring’s Behavioral Difficulties
We went on to investigate 43 PUFA containing lipid species
detected in maternal serum at the 34th week of pregnancy as a
further potential source of IL-13 increase by applying Bonferroni
corrected correlation analyses (Table 4). Strikingly, almost half
of the phosphatidylcholine lipids (17 out of 38 PC-lipids)
were negatively associated with maternal IL-13 while only the
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lipid species PC aa C38:6 remained statistically significant after
multiple testing (Spearman correlation: R = −0.21, Bonferroni
corrected p= 0.036, Supplementary Figure S1).
Due to the nature of the applied AbsoluteIDQ p180 Kit
of Biocrates to measure lipids the exact fatty acid linked to
the glycerol backbone cannot be determined. However, the
possible isotype of the phosphatidylcholine lipid PC aa C38:6
according to the LIPID MAPS structure database (45) the vast
majority (18 out of 25 lipids) of the possible PUFAs are omega-
3 and/or omega-6 fatty acids including docosahexaenoic acid
[DHA, 22:6(n-3)] and eicosapentaenoic acid [EPA, 20:5(n-3),
Supplementary Figure S2].
As PC aa C38:6 showed no direct association to the TDS
or to any of the other subscales (Supplementary Table 3), we
performed a mediation analysis to evaluate the relationship
between maternal PC aa C38:6, IL-13, and children’s behavior
at the age of eight. The models were adjusted for maternal AD
in addition to the confounding factors known to contribute
to behavioral sequelae (see Methods section). Here, an
indirect effect of PC aa C38:6 on children’s TDS as well as
hyperactive/inattentive behavior was observed, which was
based on PC aa C38:6’s negative association with gestational
IL-13 (TDS: indirect effect size (lower/upper CI):−0.47
(-1.13/−0.14), Figure 4A; hyperactivity/inattention: indirect
effect size (lower/upper CI):−0.51 (-1.18/−0.18), Figure 4B).
Association of IL-13 With PC aa C38:6 and
Their Contribution to Behavioral Sequelae
Next, we investigated whether the effect of gestational IL-13 on
the behavioral development of the children might be related to
changes in cord blood IL-13 and PC aa C38:6.
An elevated cord blood IL-13 concentration was detected
in children with abnormal behavior at the age of eight years
based on TDS classification compared to controls [adj.OR (95%
CI): 1.77 (1.09–2.87), n = 193 vs. 27, Supplementary Table 4,
for raw data see Supplementary Figure S3A]. However,
in contrast to gestational IL-13 no differential expression
was detected in hyperactive/inattentive children compared
to controls [adj. OR (95% CI): 1.23 (0.80–1.89), n =
191 vs. 29, Supplementary Table 4, for raw data see
Supplementary Figure S3B]. In line with maternal PC aa
C38:6, cord blood PC aa C38:6 is not altered in children who
later develop behavioral sequelae compared to normally behaving
children [TDS: adj.OR (95% CI): 0.96 (0.40–2.31), n= 32 vs. 203;
hyperactivity/inattention: adj.OR (95% CI): 0.84 (0.35–2.01), n
= 34 vs. 201; Supplementary Table 5].
In a subsequent mediation analysis, the mutual influence
of gestational and cord blood IL-13 as well as gestational and
cord blood PC aa C38:6 concentrations on children’s behavior
was assessed. Although, both, gestational and cord blood IL-13
were increased in children with abnormal behavior based on the
TDS (Figure 1A and Supplementary Figure S3A), gestational
IL-13 was neither directly associated with cord blood IL-13
[direct effect size (lower/upper CI): −0.13 (−0.33/0.07)] nor
with cord blood PC aa C38:6 [direct effect size (lower/upper
CI): −0.05 (−0.13/0.03), Figure 5]. In addition, the indirect
effect of gestational PC aa C38:6 on children’s behavior
was solely mediated by gestational IL-13 [indirect effect size
(lower/upper CI): −0.55 (−1.62/−0.14), Figure 5] and not
related to changes in either cord blood IL-13 [indirect effect
size (lower/upper CI): 0.03 (−0.33/0.50), Figure 5] or cord
blood PC aa C38:6 [indirect effect size (lower/upper CI):
0.00 (−0.15/0.14), Figure 5]. Applying the same mediation
model to hyperactivity/inattention, only gestational IL-13,
but not cord blood IL-13 was associated with children’s
hyperactive/inattentive behavior (Supplementary Figure S4).
DISCUSSION
Based on data of the prospective mother-child cohort LINA,
this study evaluated the influence of maternal immune
activation (MIA) during the prenatal developmental phase on
offspring’s behavioral sequelae in eight-year-old children using
the standardized SDQ. We focused on the effects of the
gestational immune status shaped by a history of maternal atopic
diseases rather than on a pathogen-mediated immune response
and could show a link between increased gestational IL-13 and
children’s hyperactivity/inattention and the TDS at the age of
eight years. Our analyses included possible alterations of the
serum lipid profile during late pregnancy, mainly focusing on
PUFA containing lipids, as PUFAs are known as critical immune
modulators. To our knowledge, this is the first study investigating
the interplay of maternal cytokine and lipid profiles during
pregnancy and their impact on children’s behavior in later life.
In particular, the end of pregnancy marks a time window
highly susceptible to maternal immune insults affecting fetal
central nervous system (CNS) development associated with
neurodevelopmental sequelae in the offspring. Nowadays, it
is well accepted that a maternal inflammatory immune status
caused by infectious diseases can increase the risk for children’s
brain-maldevelopment with behavioral consequences. There is
some reason to believe that a maternal non-pathogenic immune
activation may contribute to the development of abnormal
behavior of the child as well. Elevated maternal IFNγ and
IL-4 concentrations during pregnancy have previously been
detected in mothers who gave birth to children with later ASD
development (46). In our study, we also observed a positive
association of concentrations of both of these cytokines during
late pregnancy with hyperactive/inattentive behavior in eight-
year-old children, although these associations did not sustain
significance after multiple test correction.
However, we observed a significantly increased risk for
hyperactivity and inattention—two core-symptoms of ADHD—
for children exposed to high gestational IL-13 concentrations. In
recent years, it has become apparent that the role of IL-13 exceeds
that of a classical anti-inflammatory cytokine involved in allergy
and parasite infections (47). To date, there are indications that
IL-13 is a critical modulator in the CNS and cognition (48, 49)
and that increased IL-13 concentrations are associated with ASD
and hyperactivity/inattention, respectively (50, 51). Mechanisms
by which maternal IL-13 influence brain function of the offspring
might be alterations in neuron-microglia interaction. IL-13
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TABLE 4 | Correlation between lipid metabolites containing at least one PUFA and gestational IL-13.





Raw p-value Bonferroni corrected
p-value*
LYSOPHOSPHATIDYLCHOLINE
lysoPC a C18:2 10.78 (8.76–13.51) 0.11 0.0947 1.0000
lysoPC a C20:3 1.52 (1.28–2.04) 0.05 0.4365 1.0000
lysoPC a C20:4 3.31 (2.73–4.59) 0.09 0.1412 1.0000
PHOSPHATIDYLCHOLINE
PC aa C32:3 2.24 (1.01–3.07) −0.15 0.0211 0.9083
PC aa C34:3 69.42 (38.51–89.07) −0.16 0.0102 0.4396
PC aa C34:4 6.76 (4.07–9.8) −0.08 0.2273 1.0000
PC aa C36:3 361.92 (246.95–424.65) −0.18 0.0054 0.2343
PC aa C36:4 458.97 (295.64–560.94) −0.16 0.0140 0.6035
PC aa C36:5 44.84 (29.82–64.59) −0.10 0.1126 1.0000
PC aa C36:6 3.42 (2.37–4.9) −0.09 0.1621 1.0000
PC aa C38:3 80.45 (64.2–97.07) −0.15 0.0185 0.7939
PC aa C38:4 151.22 (119.82–183.03) −0.13 0.0474 1.0000
PC aa C38:5 94.08 (69.37–117.77) −0.12 0.0632 1.0000
PC aa C38:6 229.62 (175.17–294.09) -0.21 0.0008 0.0360
PC aa C40:3 1.2 (0.89–1.58) −0.15 0.0233 1.0000
PC aa C40:4 5.58 (4.67–6.87) −0.09 0.1517 1.0000
PC aa C40:5 14.16 (11.66–17.68) −0.08 0.2284 1.0000
PC aa C40:6 48.14 (41.58–61.66) −0.19 0.0037 0.1600
PC aa C42:4 0.4 (0.34–0.56) −0.05 0.4012 1.0000
PC aa C42:5 0.84 (0.72–1.09) −0.10 0.1371 1.0000
PC aa C42:6 1.02 (0.86–1.25) −0.05 0.4368 1.0000
PC ae C34:3 19.03 (10.75–24.25) −0.17 0.0061 0.2637
PC ae C36:3 22.33 (13.78–28.75) −0.12 0.0680 1.0000
PC ae C36:4 37.66 (25.43–47.1) −0.11 0.0735 1.0000
PC ae C36:5 20.74 (13.24–26.83) −0.16 0.0131 0.5634
PC ae C38:3 10.4 (7.15–13.1) −0.15 0.0154 0.6624
PC ae C38:4 26.39 (20.57–32.32) −0.13 0.0375 1.0000
PC ae C38:5 31.79 (22.03–37.59) −0.14 0.0267 1.0000
PC ae C38:6 15.51 (10.38–18.89) −0.11 0.0782 1.0000
PC ae C40:3 2.61 (2–3.3) −0.11 0.0789 1.0000
PC ae C40:4 4.48 (3.74–5.44) −0.07 0.3037 1.0000
PC ae C40:5 6.7 (5.38–8.31) −0.13 0.0394 1.0000
PC ae C40:6 8.88 (7.05–10.94) −0.13 0.0362 1.0000
PC ae C42:3 1.86 (1.5–2.2) −0.17 0.0071 0.3037
PC ae C42:4 1.62 (1.4–1.97) −0.02 0.7468 1.0000
PC ae C42:5 3.54 (3.05–4.11) −0.08 0.2410 1.0000
PC ae C44:3 0.35 (0.27–0.48) −0.08 0.2009 1.0000
PC ae C44:4 0.72 (0.57–0.94) 0.07 0.2784 1.0000
PC ae C44:5 2.52 (2.12–3.4) 0.11 0.0756 1.0000
PC ae C44:6 1.68 (1.38–2.04) 0.03 0.6584 1.0000
SPHINGOMYELIN
SM (OH) C22:2 4.59 (3.57–10.94) 0.12 0.0528 1.0000
SM C20:2 0.47 (0.34–0.78) 0.18 0.0046 0.1974
SM C22:3 0.53 (0.26–1.35) 0.10 0.1284 1.0000
*p-value adjusted for Bonferroni correction, n (tests) = 43.
n = 244, p < 0.05 are highlighted in bold. Significant correlation after multiple test correction is indicated in orange.
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FIGURE 4 | Gestational IL-13 mediates the indirect influence of the maternal
phosphatidylcholine lipid species PC aa C38:6 on the development of
behavioral difficulties. Mediation analyses for the relationship of the maternal
phosphatidylcholine lipid PC aa C38:6, gestational IL-13 and their impact on
the development of abnormal behavior at the age of eight based on (A) TDS or
(B) hyperactive/inattentive behavior. Tables summarize unstandardized effect
sizes (n = 243, adjusted for SDQ confounders and for the history of maternal
AD, significance determined by percentile-corrected 95% CI of 5,000
bootstrapped samples, n.a.: no p-values are calculated for this model type by
the PROCESS macro, effects are significant if confidence intervals do not
contain zero).
expression is described in rodent CA1 pyramidal neurons of
the hippocampus (52) as well as in microglia (53–55), which
are immune cells of the CNS suspected to translate MIA to
neurodevelopmental sequelae (56). In microglia, IL-13 exhibits
differing functions (53, 55, 57). While it is accepted that IL-13
concentration can increase in the brain as a result of different
infectious or inflammatory insults by activation of microglia, the
pathophysiological consequences are controversially discussed
(53, 55, 57). It has been suggested that elevated IL-13 leads
to the death of activated microglia presumably compensating
excessive inflammation in vivo (53). On the other hand, enhanced
IL-13 triggers reactive oxygen species production in microglia
through NADPH oxidase activation leading to the degeneration
of hippocampal neurons (57). However, whether these effects
of IL-13 on microglia-neuron interaction have consequences for
cognition and behavior still needs to be determined.
Findings of our study support the notion that multiple
factors influence the observed increased gestational IL-13
concentrations. We provide some evidence that one of these
factors is maternal AD, which coincided with elevated serum
IL-13 of the mothers. AD is a highly prevalent chronic,
inflammatory skin disease characterized by an aberrant systemic
immune regulation (58). Cytokines play a pivotal role in
AD pathophysiology (59). In particular, IL-13 is suspected
as a critical mediator in AD-related inflammatory processes
(58). In agreement with our results, peripheral blood IL-13
concentrations are consistently described as being elevated in
AD patients (60). However, our data suggests that although
maternal AD seems to contribute to elevated maternal IL-13,
maternal AD itself is not associated with children’s TDS or
hyperactivity/inattention. Supported by the finding that maternal
IL-13 is also linked to children’s behavior in the absence of a
maternal AD. This result strongly suggested that further factors
influencing maternal IL-13 concentrations potentially play a role
in the development of children’s behavioral abnormalities.
PUFAs have a well-described immune-regulatory function
and contribute to cytokine homeostasis. For instance, n-3-PUFA
exhibit an anti-inflammatory role by inhibiting inflammatory
cytokine production possibly via NR1C3, NFκB, or modulating
immune cell activity (61). We observed that high concentrations
of maternal IL-13 were also associated with a decrease in the
PUFA containing phosphatidylcholine PC aa C38:6 measured in
blood sera from the 34th week of pregnancy. These results are
consistent with a previous study showing decreased cord blood
IL-13 following a PUFA-rich fish oil supplementation during
pregnancy (62). Furthermore, lower PUFA concentrations have
been found in children with ADHD compared to controls
(63, 64) supporting a potential relevance of PUFAs for
behavioral abnormalities.
Two possible isomers of PC aa C38:6 contain docosahexaenoic
acid (DHA) or eicosapentaenoic acid (EPA), two omega 3-
fatty acids essential for healthy brain development (18). Several
agencies (e.g., Food and Agriculture Organization of the United
Nations, EFSA) recommend supplementation with DHA and
EPA for pregnant and lactating women to compensate for
increased needs of fetal development particularly of the brain (65,
66). However, randomized control trials were not able to show an
apparent beneficial effect of omega-3 fatty acid supplementation
during pregnancy on offspring’s neurodevelopment (67, 68).
Although, we provide some evidence that maternal as well
as cord blood IL-13 are associated with behavioral sequelae
in children, they both seem to act independently. Gestational
IL-13 was not associated with cord blood IL-13, which is in
line with previous observations showing that although maternal
Th2 cytokines like IL-5 and IL-6 are related to children’s
cytokine concentrations at a very early age, for IL-13 no
clear relationship has been shown (69). The distinct effects
of maternal and fetal IL-13 are supported by the fact that
in contrast to gestational PC aa C38:6 cord blood PC aa
C38:6 are not associated with changes in IL-13 concentration.
This observation suggests that the risk increase for behavioral
abnormalities by cord blood IL-13 is independent of PC aa C38:6.
Notably, only gestational IL-13, but not cord blood IL-13 was
linked to an increased risk to develop hyperactivity/inattention.
Therefore, although we observe a mutual deleterious effect
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FIGURE 5 | Influence of lipid species PC aa C38:6 and IL-13 on the development of abnormal behavior based on TDS. Mediation analysis of PC aa C38:6 and IL-13
and their impact on abnormal behavior (TDS). Tables summarize unstandardized effect sizes (n = 177, adjusted for SDQ confounders and for the history of maternal
AD, significance determined by percentile-corrected 95% CI of 5,000 bootstrapped samples, n.a.: no p-values are calculated for this model type by the PROCESS
macro, effects are significant if confidence intervals do not contain zero).
of maternal and cord blood IL-13 on children’s behavior, it
seems that in particular gestational PC aa C38:6 and IL-
13 might have a profound influence on brain-development
with a long-term impact on behavioral sequelae including
childhood hyperactivity/inattention.
Although also previous studies did not observe a direct
advantageous effect of omega-3 fatty acid supplementation
on children’s cognitive outcomes, still our data suggest that
a balanced lipid composition during pregnancy is important
to sustain cytokine homeostasis (70). Even if transient,
such deviations in cytokine homeostasis during critical
time windows of development can promote an aberrant
CNS architecture leading to an altered brain function in
later life.
The findings of this study have to be seen in the light of
some limitations. An apparent limitation of our study is the
applied metabolome analysis not enabling the determination of
specific fatty acids. Thus, we were not able to study the role of
maternal PUFA concentration in late pregnancy in more detail
and with more accuracy. It is also important to point out that the
measurement of PUFAs was performed in serum sample, while
the cytokine profile was analyzed in plasma. Although, absolute
concentrations might differ between these two different matrices,
relative behavior of PUFAs and cytokines should not be affected.
Of note, the number of children born to mothers without atopic
comorbidities was insufficient to restrict our analysis to only
those children. Therefore, we cannot exclude the possibility that
also other atopic diseases might contribute to an elevation in
maternal IL-13. However, when adjusting our regression analysis
for asthma the positive association of maternal AD on IL-
13 was sustained. We are also aware of the fact that the use
of questionnaires for outcome definition provides less reliable
results compared to a clinical diagnosis. Nevertheless, since
the applied SDQ is a well-accepted tool validated in numerous
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studies, we are firmly convinced that the results of this study can
add substantial new knowledge to the field (29, 30, 71).
For the first time, we identified increased gestational and cord
blood IL-13 as risk factors for the development of behavioral
difficulties at a later age. Given the fact that IL-13 emerged as a
promising target for neurodevelopmental diseases therapy and is
already a therapeutic target for allergy treatment (47), a better
understanding of maternal-fetal IL-13 signaling in early brain
development is warranted. Therefore, we emphasize to include
IL-13 in future studies on MIA mediated psychopathological
sequelae of the offspring and to consider pro- and anti-
inflammatory cytokines and detailed fatty acid composition in
the analyses to investigate whether the presented findings can be
validated in independent studies.
DATA AVAILABILITY
The datasets for this manuscript regarding the LINA cohort
generated and/or analyzed in the current study are not publicly
available due to limited consent of the study participants
but are available from the corresponding author upon
reasonable request.
ETHICS STATEMENT
This study was carried out in accordance with the declaration of
Helsinki and was approved by the Institutional Review Board of
the University of Leipzig (046-2006, 150/14-ff). Participation in
the study was voluntary and informed written consent was given
by the parents.
AUTHOR CONTRIBUTIONS
MB, SR, GH, and IL designed the LINA study, were
responsible for the fieldwork and provided proband materials.
GH, UR-K, MvB, and IL performed and/or coordinated
cytokine and metabolomics measurements. LT and ST
performed data analysis. LT, IL, and ST prepared the initial
manuscript and figures. All authors contributed to the
final manuscript.
ACKNOWLEDGMENTS
We would like to thank Beate Fink, Michaela Loschinski,
Anna Regis, Laureen Winzer, André Andrecke, and
Melanie Bänsch for their excellent technical assistance
and fieldwork. We cordially thank the participants of the
LINA study.
SUPPLEMENTARY MATERIAL




1. Schepanski S, Buss C, Hanganu-Opatz IL, Arck PC. Prenatal immune
and endocrine modulators of offspring’s brain development and
cognitive functions later in life. Front Immunol. (2018) 9:2186.
doi: 10.3389/fimmu.2018.02186
2. Estes ML, McAllister AK. Maternal immune activation: implications
for neuropsychiatric disorders. Science. (2016) 353:772–7.
doi: 10.1126/science.aag3194
3. Ashdown H, Dumont Y, Ng M, Poole S, Boksa P, Luheshi GN. The
role of cytokines in mediating effects of prenatal infection on the
fetus: implications for schizophrenia. Mol Psychiatry. (2006) 11:47–55.
doi: 10.1038/sj.mp.4001748
4. Patterson PH. Maternal infection and immune involvement in autism. Trends
Mol Med. (2011) 17:389–94. doi: 10.1016/j.molmed.2011.03.001
5. WerenbergDreier J, NyboAndersenAM,Hvolby A, Garne E, KraghAndersen
P, Berg-Beckhoff G. Fever and infections in pregnancy and risk of attention
deficit/hyperactivity disorder in the offspring. J Child Psychol Psychiatry.
(2016) 57:540–8. doi: 10.1111/jcpp.12480
6. Fedorova I, Hussein N, BaumannMH, Di Martino C, Salem N Jr. An n-3 fatty
acid deficiency impairs rat spatial learning in the Barnesmaze. Behav Neurosci.
(2009) 123:196–205. doi: 10.1037/a0013801
7. Knuesel I, Chicha L, Britschgi M, Schobel SA, Bodmer M, Hellings JA, et al.
Maternal immune activation and abnormal brain development across CNS
disorders. Nat Rev Neurol. (2014) 10:643–60. doi: 10.1038/nrneurol.2014.187
8. Meyer U, Feldon J, Yee BK. A review of the fetal brain cytokine
imbalance hypothesis of schizophrenia. Schizophr Bull. (2009) 35:959–72.
doi: 10.1093/schbul/sbn022
9. Brown AS, Hooton J, Schaefer CA, Zhang H, Petkova E, Babulas V, et al.
Elevated maternal interleukin-8 levels and risk of schizophrenia in adult
offspring. Am J Psychiatry. (2004) 161:889–95. doi: 10.1176/appi.ajp.161.5.889
10. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Wagner RL, Yolken RH.
Maternal cytokine levels during pregnancy and adult psychosis. Brain Behav
Immun. (2001) 15:411–20. doi: 10.1006/brbi.2001.0644
11. Ghassabian A, Albert PS, Hornig M, Yeung E, Cherkerzian S, Goldstein RB,
et al. Gestational cytokine concentrations and neurocognitive development at
7 years. Transl Psychiatry. (2018) 8:64. doi: 10.1038/s41398-018-0112-z
12. Rudolph MD, Graham AM, Feczko E, Miranda-Dominguez O, Rasmussen
JM, Nardos R, et al. Maternal IL-6 during pregnancy can be estimated from
newborn brain connectivity and predicts future workingmemory in offspring.
Nat Neurosci. (2018) 21:765–72. doi: 10.1038/s41593-018-0128-y
13. Ginsberg Y, Khatib N, Weiner Z, Beloosesky R. Maternal inflammation, fetal
brain implications and suggested neuroprotection: a summary of 10 years
of research in animal models. Rambam Maimonides Med J. (2017) 8:e0028.
doi: 10.5041/RMMJ.10305
14. Wu WL, Hsiao EY, Yan Z, Mazmanian SK, Patterson PH. The placental
interleukin-6 signaling controls fetal brain development and behavior. Brain
Behav Immun. (2017) 62:11–23. doi: 10.1016/j.bbi.2016.11.007
15. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune
activation alters fetal brain development through interleukin-6. J Neurosci.
(2007) 27:10695–702. doi: 10.1523/JNEUROSCI.2178-07.2007
16. Nielsen PR, Benros ME, Dalsgaard S. Associations between autoimmune
diseases and attention-deficit/hyperactivity disorder: a nationwide
study. J Am Acad Child Adolesc Psychiatry. (2017) 56:234–40 e231.
doi: 10.1016/j.jaac.2016.12.010
17. Croen LA, Grether JK, Yoshida CK, Odouli R, Van de Water J. Maternal
autoimmune diseases, asthma and allergies, and childhood autism spectrum
disorders: a case-control study. Arch Pediatr Adolesc Med. (2005) 159:151–7.
doi: 10.1001/archpedi.159.2.151
18. Lauritzen L, Brambilla P, Mazzocchi A, Harslof LB, Ciappolino V, Agostoni
C. DHA effects in brain development and function. Nutrients. (2016) 8:6.
doi: 10.3390/nu8010006
Frontiers in Immunology | www.frontiersin.org 12 July 2019 | Volume 10 | Article 1658
Thürmann et al. Gestational IL-13 and Hyperactive/Inattentive Behavior
19. McNamara RK, Carlson SE. Role of omega-3 fatty acids in brain development
and function: potential implications for the pathogenesis and prevention of
psychopathology. Prostaglandins Leukot Essent Fatty Acids. (2006) 75:329–49.
doi: 10.1016/j.plefa.2006.07.010
20. Lamptey MS, Walker BL. Learning behavior and brain lipid composition in
rats subjected to essential fatty acid deficiency during gestation, lactation and
growth. J Nutr. (1978) 108:358–67. doi: 10.1093/jn/108.3.358
21. Maekawa M, Watanabe A, Iwayama Y, Kimura T, Hamazaki K, Balan
S, et al. Polyunsaturated fatty acid deficiency during neurodevelopment
in mice models the prodromal state of schizophrenia through epigenetic
changes in nuclear receptor genes. Transl Psychiatry. (2017) 7:e1229.
doi: 10.1038/tp.2017.182
22. Lim SY, Hoshiba J, Moriguchi T, Salem N Jr. N-3 fatty acid deficiency
induced by a modified artificial rearing method leads to poorer
performance in spatial learning tasks. Pediatr Res. (2005) 58:741–8.
doi: 10.1203/01.PDR.0000180547.46725.CC
23. Carrie I, Guesnet P, Bourre JM, Frances H. Diets containing long-chain
n-3 polyunsaturated fatty acids affect behaviour differently during
development than ageing in mice. Br J Nutr. (2000) 83:439–47.
doi: 10.1017/S0007114500000544
24. Gould JF, Treyvaud K, Yelland LN, Anderson PJ, Smithers LG, Gibson RA,
et al. Does n-3 LCPUFA supplementation during pregnancy increase the IQ
of children at school age? Follow-up of a randomised controlled trial. BMJ
Open. (2016) 6:e011465. doi: 10.1136/bmjopen-2016-011465
25. Chang JP, Su KP, Mondelli V, Pariante CM. Omega-3 polyunsaturated
fatty acids in youths with attention deficit hyperactivity disorder: a
systematic review and meta-analysis of clinical trials and biological
studies. Neuropsychopharmacology. (2018) 43:534–45. doi: 10.1038/npp.
2017.160
26. Algorta GP, Dodd AL, Stringaris A, Youngstrom EA. Diagnostic efficiency of
the SDQ for parents to identify ADHD in the UK: a ROC analysis. Eur Child
Adolesc Psychiatry. (2016) 25:949–57. doi: 10.1007/s00787-015-0815-0
27. Mathai J, Anderson P, Bourne A. Comparing psychiatric diagnoses
generated by the Strengths and Difficulties Questionnaire with
diagnoses made by clinicians. Aust N Z J Psychiatry. (2004) 38:639–43.
doi: 10.1080/j.1440-1614.2004.01428.x
28. Overgaard KR, Oerbeck B, Friis S, Pripp AH, Biele G, Aase H, et al.
Attention-deficit/hyperactivity disorder in preschoolers: the accuracy of a
short screener. J Am Acad Child Adolesc Psychiatry. (2018) 57:428–35.
doi: 10.1016/j.jaac.2018.03.008
29. Russell G, Rodgers LR, Ford T. The strengths and difficulties questionnaire
as a predictor of parent-reported diagnosis of autism spectrum disorder
and attention deficit hyperactivity disorder. PLoS ONE. (2013) 8:e80247.
doi: 10.1371/journal.pone.0080247
30. Ullebo AK, Posserud MB, Heiervang E, Gillberg C, Obel C. Screening for
the attention deficit hyperactivity disorder phenotype using the strength
and difficulties questionnaire. Eur Child Adolesc Psychiatry. (2011) 20:451–8.
doi: 10.1007/s00787-011-0198-9
31. Goodman R. The strengths and difficulties questionnaire: a
research note. J Child Psychol Psychiatry. (1997) 38:581–6.
doi: 10.1111/j.1469-7610.1997.tb01545.x
32. Overgaard KR, Madsen KB, Oerbeck B, Friis S, Obel C. The predictive
validity of the Strengths and Difficulties Questionnaire for child attention-
deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. (2018) 28:625–33.
doi: 10.1007/s00787-018-1226-9
33. Woerner W, Becker A, Friedrich C, Klasen H, Goodman R, Rothenberger
A. Normal values and evaluation of the German parents’ version of
Strengths and Difficulties Questionnaire (SDQ): results of a representative
field study. Z Kinder Jugendpsychiatr Psychother. (2002) 30:105–12.
doi: 10.1024/1422-4917.30.2.105
34. Herberth G, Hinz D, Roder S, Schlink U, Sack U, Diez U, et al. Maternal
immune status in pregnancy is related to offspring’s immune responses and
atopy risk. Allergy. (2011) 66:1065–74. doi: 10.1111/j.1398-9995.2011.02587.x
35. Thurmann L, Grützmann K, Klös M, Bieg M, Winter M, Polte T, et al. Early-
onset childhood atopic dermatitis is related to NLRP2 repression. J Allergy
Clin Immunol. (2018) 141:1482–5 e1416. doi: 10.1016/j.jaci.2017.11.018
36. Herberth G, Offenberg K, Rolle-Kampczyk U, Bauer M, Otto W, Röder S,
et al. Endogenous metabolites and inflammasome activity in early childhood
and links to respiratory diseases. J Allergy Clin Immunol. (2015) 136:495–7.
doi: 10.1016/j.jaci.2015.01.022
37. Hayes AF. Introduction to Mediation, Moderation, and Conditional Process
Analysis: A Regression-Based Approach.New York, NY: Guilford Press (2013).
38. Becker A, Steinhausen HC, Baldursson G, Dalsgaard S, Lorenzo MJ, Ralston
SJ, et al. Psychopathological screening of children with ADHD: Strengths
and Difficulties Questionnaire in a pan-European study. Eur Child Adolesc
Psychiatry. (2006) 15 (Suppl. 1):I56–62. doi: 10.1007/s00787-006-1008-7
39. Chastang J, Baïz N, Cadwalladder JS, Robert S, Dywer J, Charpin
DA, et al. Postnatal environmental tobacco smoke exposure related
to behavioral problems in children. PLoS ONE. (2015) 10:e0133604.
doi: 10.1371/journal.pone.0133604
40. Hosokawa R, Katsura T. Effect of socioeconomic status on behavioral
problems from preschool to early elementary school - A Japanese longitudinal
study. PLoS ONE. (2018) 13:e0197961. doi: 10.1371/journal.pone.0197961
41. Lewis H,Hope S, Pearce A. Socioeconomic inequalities in parent-reported and
teacher-reported psychological well-being. Arch Dis Child. (2015) 100:38–41.
doi: 10.1136/archdischild-2014-306288
42. Niclasen J, Nybo Andersen AM, Teasdale TW, Strandberg-Larsen K.
Prenatal exposure to alcohol, and gender differences on child mental health
at age seven years. J Epidemiol Community Health. (2014) 68:224–32.
doi: 10.1136/jech-2013-202956
43. Arbuckle TE, Davis K, Boylan K, Fisher M, Fu J. Bisphenol A, phthalates
and lead and learning and behavioral problems in Canadian children
6–11 years of age: CHMS 2007-2009. Neurotoxicology. (2016) 54:89–98.
doi: 10.1016/j.neuro.2016.03.014
44. Buhlmeier J, Harris C, Koletzko S, Lehmann I, Bauer CP, Schikowski T, et al.
Dietary acid load and mental health outcomes in children and adolescents:
results from the GINIplus and LISA birth cohort studies. Nutrients. (2018)
10:582. doi: 10.3390/nu10050582
45. Sud M, Fahy E, Cotter D, Brown A, Dennis EA, Glass CK, et al. LMSD:
LIPID MAPS structure database. Nucleic Acids Res. (2007) 35:D527–32.
doi: 10.1093/nar/gkl838
46. Goines PE, Croen LA Braunschweig D, Yoshida CK, Grether J, Hansen
R, et al. Increased midgestational IFN-gamma, IL-4 and IL-5 in women
bearing a child with autism: a case-control study. Mol Autism. (2011) 2:13.
doi: 10.1186/2040-2392-2-13
47. Karo-Atar D, Bitton A, Benhar I, Munitz A. Therapeutic targeting of
the interleukin-4/interleukin-13 signaling pathway: in allergy and beyond.
Biodrugs. (2018) 32:201–20. doi: 10.1007/s40259-018-0280-7
48. Brombacher TM, Nono JK, De Gouveia KS, Makena N, Darby M, Womersley
J, et al. IL-13-mediated regulation of learning and memory. J Immunol. (2017)
198:2681–8. doi: 10.4049/jimmunol.1601546
49. Mori S, Maher P, Conti B. Neuroimmunology of the Interleukins 13 and 4.
Brain Sci. (2016) 6:18. doi: 10.3390/brainsci6020018
50. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de
Water J. Altered T cell responses in children with autism. Brain Behav Immun.
(2011) 25:840–9. doi: 10.1016/j.bbi.2010.09.002
51. Oades RD, Myint AM, Dauvermann MR, Schimmelmann BG, Schwarz
MJ. Attention-deficit hyperactivity disorder (ADHD) and glial integrity:
an exploration of associations of cytokines and kynurenine metabolites
with symptoms and attention. Behav Brain Funct. (2010) 6:32.
doi: 10.1186/1744-9081-6-32
52. Yu JT, Lee CH, Yoo KY, Choi JH, Li H, Park OK, et al. Maintenance of
anti-inflammatory cytokines and reduction of glial activation in the ischemic
hippocampal CA1 region preconditioned with lipopolysaccharide. J Neurol
Sci. (2010) 296:69–78. doi: 10.1016/j.jns.2010.06.004
53. Shin WH, Lee DY, Park KW, Kim SU, Yang MS, Joe EH, et al.
Microglia expressing interleukin-13 undergo cell death and contribute
to neuronal survival in vivo. Glia. (2004) 46:142–52. doi: 10.1002/glia.
10357
54. Yang MS, Ji KA, Jeon SB, Jin BK, Kim SU, Jou I, et al. Interleukin-
13 enhances cyclooxygenase-2 expression in activated rat brain microglia:
implications for death of activated microglia. J Immunol. (2006) 177:1323–9.
doi: 10.4049/jimmunol.177.2.1323
55. Yang MS, Park EJ, Sohn S, Kwon HJ, Shin WH, Pyo HK, et al. Interleukin-
13 and−4 induce death of activated microglia. Glia. (2002) 38:273–80.
doi: 10.1002/glia.10057
Frontiers in Immunology | www.frontiersin.org 13 July 2019 | Volume 10 | Article 1658
Thürmann et al. Gestational IL-13 and Hyperactive/Inattentive Behavior
56. Smolders S, Notter T, Smolders SMT, Rigo JM, Brone B. Controversies
and prospects about microglia in maternal immune activation models
for neurodevelopmental disorders. Brain Behav Immun. (2018) 73:51–65.
doi: 10.1016/j.bbi.2018.06.001
57. Park KW, Baik HH, Jin BK. IL-13-induced oxidative stress via microglial
NADPH oxidase contributes to death of hippocampal neurons in vivo. J
Immunol. (2009) 183:4666–74. doi: 10.4049/jimmunol.0803392
58. Simon D, Wollenberg A, Renz H, Simon HU. Atopic dermatitis: Collegium
Internationale Allergologicum (CIA) update. Int Arch Allergy Immunol.
(2019) 178:207–218. doi: 10.1159/000497383
59. Carmi-Levy I, Homey B, Soumelis V. A modular view of cytokine
networks in atopic dermatitis. Clin Rev Allergy Immunol. (2011) 41:245–53.
doi: 10.1007/s12016-010-8239-6
60. Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell
Immunol. (2011) 2:110. doi: 10.4172/2155-9899.1000110
61. Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes:
nutrition or pharmacology? Br J Clin Pharmacol. (2013) 75:645–62.
doi: 10.1111/j.1365-2125.2012.04374.x
62. Krauss-Etschmann S, Hartl D, Rzehak P, Heinrich J, Shadid R, Del Carmen
Ramírez-Tortosa M, et al. Decreased cord blood IL-4, IL-13, and CCR4 and
increased TGF-beta levels after fish oil supplementation of pregnant women. J
Allergy Clin Immunol. (2008) 121:464–70 e466. doi: 10.1016/j.jaci.2007.09.018
63. Hawkey E, Nigg JT. Omega-3 fatty acid and ADHD: blood level
analysis and meta-analytic extension of supplementation trials.
Clin Psychol Rev. (2014) 34:496–505. doi: 10.1016/j.cpr.2014.
05.005
64. Tesei A, Crippa A, Ceccarelli SB, Mauri M, Molteni M, Agostoni C,
et al. The potential relevance of docosahexaenoic acid and eicosapentaenoic
acid to the etiopathogenesis of childhood neuropsychiatric disorders. Eur
Child Adolesc Psychiatry. (2017) 26:1011–30. doi: 10.1007/s00787-016-
0932-4
65. EFSA. Scientific Opinion on Dietary Reference Values for fats, including
saturated fatty acids, polyunsaturated fatty acids, monounsaturated
fatty acids, trans fatty acids, and cholesterol. EFSA J. (2010) 8:1461.
doi: 10.2903/j.efsa.2010.1461
66. FaAOotUN. Fats and Fatty Acids in Human Nutrition: Report of An Expert
Consultation. Rome, Italy (2010).
67. Meldrum S, Simmer K. Docosahexaenoic acid and neurodevelopmental
outcomes of term infants. Ann Nutr Metab. (2016) 69 (Suppl. 1):22–8.
doi: 10.1159/000448271
68. Middleton P, Gomersall JC, Gould JF, Shepherd E, Olsen SF, Makrides
M. Omega-3 fatty acid addition during pregnancy. Cochrane Database
Syst Rev. (2018) 11:CD003402. doi: 10.1002/14651858.CD003402.
pub3
69. Djuardi Y, Supali T, Wibowo H, Heijmans BT, Deelen J, Slagboom
EP, et al. Maternal and child cytokine relationship in early life is not
altered by cytokine gene polymorphisms. Genes Immun. (2016) 17:380–5.
doi: 10.1038/gene.2016.35
70. Gould JF, Smithers LG, Makrides M. The effect of maternal omega-
3 (n-3) LCPUFA supplementation during pregnancy on early childhood
cognitive and visual development: a systematic review and meta-analysis
of randomized controlled trials. Am J Clin Nutr. (2013) 97:531–44.
doi: 10.3945/ajcn.112.045781
71. Goodman R, Renfrew D, Mullick M. Predicting type of psychiatric
disorder from Strengths and Difficulties Questionnaire (SDQ)
scores in child mental health clinics in London and Dhaka. Eur
Child Adolesc Psychiatry. (2000) 9:129–34. doi: 10.1007/s007870
050008
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Thürmann, Herberth, Rolle-Kampczyk, Röder, Borte, von Bergen,
Lehmann and Trump. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 14 July 2019 | Volume 10 | Article 1658
